DEFIBROTIDE SHOWS EFFICACY IN THE PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY ON 237 PATIENTS.

[1]  M. Cairo,et al.  Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation , 2020, British journal of haematology.

[2]  P. Richardson,et al.  Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced intensity allogeneic hematopoietic cell transplantation. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  P. Richardson,et al.  Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group , 2019, Bone Marrow Transplantation.

[4]  M. Pasquini,et al.  Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  P. Richardson,et al.  Defibrotide for the treatment of hepatic veno‐occlusive disease/sinusoidal obstruction syndrome following nontransplant‐associated chemotherapy: Final results from a post hoc analysis of data from an expanded‐access program , 2018, Pediatric blood & cancer.

[6]  A. Schulz,et al.  Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation , 2017, Bone Marrow Transplantation.

[7]  P. Richardson,et al.  Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  M. Abecassis,et al.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.

[9]  R. D'Agostino,et al.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.

[10]  M. Abecassis,et al.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.

[11]  G. Keating.  Defibrotide: A Review of Its Use in Severe Hepatic Veno-Occlusive Disease Following Haematopoietic Stem Cell Transplantation , 2014, Clinical Drug Investigation.

[12]  P. Richardson,et al.  Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation , 2012, Expert review of hematology.

[13]  A. Schulz,et al.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.

[14]  M. Díaz-Ricart,et al.  Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.

[15]  M. Díaz-Ricart,et al.  Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  Allen R. Chen,et al.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  B. Chapuis,et al.  Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  D. Perry,et al.  Veno-occlusive disease: cytokines, genetics, and haemostasis. , 2003, Blood reviews.

[19]  Allen R. Chen,et al.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.

[20]  A. Mcmillan,et al.  Hepatic Venoocclusive Disease in Blood and Bone Marrow Transplantation in Children and Young Adults: Incidence, Risk Factors, and Outcome in a Cohort of 241 Patients , 2002, Journal of pediatric hematology/oncology.

[21]  M. Remberger,et al.  Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.

[22]  Ha Yeon Lee,et al.  A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[23]  G. McDonald,et al.  Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). , 2002, Seminars in liver disease.

[24]  R. Miralbell,et al.  Total body irradiation before allogeneic bone marrow transplantation: is more dose better? , 2001, International journal of radiation oncology, biology, physics.

[25]  T. Barbui,et al.  Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study , 2000, British journal of haematology.

[26]  E. Carreras.  Veno‐occlusive disease of the liver after hemopoietic cell transplantation , 2000, European journal of haematology.

[27]  R S McCuskey,et al.  Characterization of a reproducible rat model of hepatic veno‐occlusive disease , 1999, Hepatology.

[28]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[29]  D. Neuberg,et al.  Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.

[30]  W. Wilmanns,et al.  Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. , 1997, Blood.

[31]  N. Kaplowitz,et al.  Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease , 1996 .

[32]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[33]  G. McDonald,et al.  Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms , 1994, Hepatology.

[34]  G. Anderson,et al.  Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Grañena,et al.  Hepatic veno-occlusive disease after bone marrow transplant. , 1993, Blood reviews.

[36]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[37]  P. Brousset,et al.  Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. , 1992, Blood.

[38]  E. Gluckman,et al.  Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. , 1991, Thrombosis research.

[39]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[40]  A. Gown,et al.  Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. , 1987, The American journal of pathology.

[41]  B. Rollins.  Hepatic veno-occlusive disease. , 1986, The American journal of medicine.

[42]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[43]  E. Horwitz,et al.  Anicteric veno-occlusive disease after hematopoietic stem cell transplantation in children , 2016, Bone Marrow Transplantation.

[44]  M. Labopin,et al.  Comparison of RIC-alloHCT and autoHCT for > 55 years old patients with acute lymphoblastic leukemia: an analysis from Acute Leukemia Working Party of the EBMT , 2015 .

[45]  P. Ljungman,et al.  Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. , 1998, Blood.

[46]  Pankaj Sharma,et al.  Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.